TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Whole Genome Sequencing (WGS) Long Read Equipment & Consumables

Blood-testing reagents
Laboratory reagents
Laboratory
+3 more
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Genomics England: "Whole Genome Sequencing (WGS) Long Read Equipment & Consumables". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityGenomics EnglandScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Genomics England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Genomics England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3Bids / Report
50% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 3 active published awards; 2 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityGenomics England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published15 Mar 2021, 22:56 GMT
Last source update15 Mar 2021, 22:56 GMT
Recurring procurementNot published
ClassificationBlood-testing reagents, Laboratory reagents, Laboratory, optical and precision equipments (excl. glasses), Medical consumables, Miscellaneous medical devices and products
Delivery area
UK
OCIDocds-h6vhtk-029bf5
What is being bought
A large-scale Long Read Whole Genome Sequencing (WGS) project using Oxford Nanopore Technologies long read technology in order to evaluate its potential for clinical use in cancer.
What changed
From the official release history
  1. Status changed to complete
    15 Mar 2021, 22:56 GMT
  2. Official notice release published
    15 Mar 2021, 22:56 GMT
  3. Buyer information updated
    15 Mar 2021, 22:56 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    Genomics England has a Spending Review (SR) objective involving a large-scale long read whole genome sequencing (WGS) project. In order to deliver this long read WGS project Genomics England have engaged and are proposing to partner with Oxford Nanopore Technologies Limited (ONT) to maximise its long read technology at scale to evaluate its potential for clinical use in cancer. This project requires sequencing at scale of around 2,000 germline:tumour pairs over the next 12 month period. A beneficial commercial agreement that represents the unique nature of the engagement in terms of technological development and value has been agreed between the parties to deliver the scope of this project in its entirety. ONT occupy a unique position in the sequencing market globally in terms of read length and throughput technology that makes this project viable. The primary sequencing instrument within this project is the Promethion P48 consuming Flowcell reagents and other associated consumables. A combination of these attributes will deliver the scaling required for the project and the commercial agreement between the parties ensures successful sequencing objectives for clinical use in cancer, within the 12 month SR period.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    15 Mar 2021, 22:56 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 15 Mar 2021, 00:00 GMT · £2,000,000
Commercial outcome and competition
Awards
Oxford Nanopore Technologies Limited
Not published · Not published · active
Contracts
Whole Genome Sequencing (WGS) Long Read Equipment & Consumables
£2,000,000 · signed 15 Mar 2021, 00:00 GMT · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

Genomics England

Contracting authority GB-FTS-8859
View buyer profile

  • Genomics England
    buyer

    Dawson Hall, Charterhouse Square, London, UK, EC1M 6BQ
    paul.nicholson@genomicsengland.co.uk
    +44 2078825030

  • Oxford Nanopore Technologies Limited
    supplier

    Oxford, UK

  • The High Court
    reviewBody

    Strand, London, WC2A 2LL
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThe Contracting Authority (i) has a legal personality; (ii) is mainly funded by the Department of Health and Social Care; and (iii) has been established for the specific purpose of meeting needs in the general interest and does not have an industrial or commercial character and therefore meets the definition of a "body governed by public law" under the Public Contracts Regulations 2015 ("PCR"). The PCR covers "public contracts" which means contracts for pecuniary interest which have as their object the execution of works, the supply of products or the provision of services. The Contract is a goods or services contract under PCR, therefore, caught by the PCR and bound to follow public procurement rules. Regulation 32(2)(b)(ii) PCR describes the single operator exclusion and is the premise for this award without prior publication. This specific exclusion relates to a demonstration that only Oxford Nanopore Technologies Limited could deliver the goods and services described for technical reasons and reasons of scalability, where the goods and services cannot be obtained from any other economic operator to sufficiently meet the volume throughput of long read whole genome sequencing. The scope of requirements in this notice are the basis for this assessment. For technical reasons, it has been determined that Oxford Nanopore Technologies Limited are the only provider able to meet the justified requirements set out. Furthermore, they are also the only organisation able to deliver the requirement at the scale specified. Further details are provided within this notice and should be read in conjunction with this explanation. The Contracting Authority will enter into a contract with Oxford Nanopore Technologies Limited following the conclusion of a minimum 10-day standstill period from the date of issue of this notice. The 10-day standstill period will end on Thursday 25th March 2021 at 11.59pm GMT, enabling a contract to be signed on Friday 26th March 2021.